Drug Profile
Tetanus-reduced diphtheria-acellular pertussis vaccine - BioNet-Asia
Alternative Names: Reduced dose Tdap vaccine; TdaP - BioNetLatest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator BioNet-Asia
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Diphtheria; Pertussis; Tetanus
Most Recent Events
- 30 Jun 2023 BioNet-Asia completes a phase II WoMANPOWER trial in Pertussis (In adults, In neonates, Prevention) in Uganda (IM) (NCT04589312)
- 05 Dec 2022 Phase-II development is ongoing in Uganda
- 18 Aug 2021 BioNet-Asia completes a phase II trial for Pertussis (In volunteers) in Thailand (TCTR20180725004)